22.02.2023 - 23.02.2023Boston Park Plaza, 50 Park Plaza, 02116 Boston, USA
Time: 8:00 am to 6:00 pm
Conference themes With strong effectiveness profiles and 20 years of FDA approval, kinase inhibitors have revolutionized oncology treatment. The success of current kinase inhibitor classes is nevertheless constrained by rising resistance and security concerns.
Scientific Society Hanson Wade
Notes Speakers: Erik Schaefer, Co-Founder, President, Chief Executive Officer and Chief Scientific Officer, AssayQuant Technologies Inc., Gerhard Mueller, Chief Scientific Officer, Anavo Therapeutics, Harish Dave, Chief Medical Officer, AUM Biosciences